Amgen Biosimilars | KANJINTI® (trastuzumab-anns) for HCPs

Indications

Adjuvant Breast Cancer

KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature*)…Read more breast cancer:

KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one
high-risk feature*) breast cancer…Read more:

As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
As part of treatment with docetaxel and carboplatin
As a single agent following multi-modality anthracycline-based therapy

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

*High-risk is defined as ER/PR positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.

Metastatic Breast Cancer

KANJINTI® is indicated:

In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

Metastatic Gastric Cancer

KANJINTI® is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with
HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment
for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

Amgen is a leader in biologics with a growing portfolio of biosimilars.

HERITAGE

The healthcare community has been able to trust us for decades

AMGEN Biologics – over 40 years of experience

AMGEN Biologics – over 40 years of experience

AMGEN Biologics – over 40 years of experience

AT AMGEN, WE’RE COMMITTED TO DELIVERING QUALITY PRODUCTS TO EVERY PATIENT, EVERY TIME

EXPERTISE

Real-world experience and expertise paved the way for our leadership in biosimilars

Over 300 Quality Checks During Manufacturing

Over 300 Quality Checks During Manufacturing

*Available biosimilars across all global markets.

Commitment

WE ARE A LONG-STANDING BIOTECHNOLOGY LEADER COMMITTED TO
DEVELOPING THE BIOSIMILAR MARKETPLACE

Invested in the development of biosimilars and novel therapeutics

In the last decade, AMGEN® has achieved zero supply shortages

In the last decade, AMGEN® has achieved zero supply shortages

Support

WE ARE COMMITTED TO PROVIDING SOLUTION-ORIENTED RESOURCES THAT CAN HELP PROVIDE POSITIVE BIOSIMILAR EXPERIENCES

Amgen Support

Amgen Support